Following controversial Aduhelm approval, DC-based neurology center bans Biogen representatives from its offices — report
CEO Michael Vounatsos confessed earlier this month that Biogen was struggling to get its controversial new Alzheimer’s drug Aduhelm off the ground, with some major health systems refusing to administer it.
Now, a DC-based medical center is taking its small rebellion against the drug’s approval one step further.
The Neurology Center has reportedly banned all Biogen representatives from its seven DC-area offices, according to a photo circulating on Twitter.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 119,800+ biopharma pros reading Endpoints daily — and it's free.